Last reviewed · How we verify
Oxis
Oxis is an oxygen therapy device used to increase oxygen levels in the blood.
Oxis is an oxygen therapy device used to increase oxygen levels in the blood. Used for Treatment of hypoxemia in patients with chronic obstructive pulmonary disease (COPD) or other respiratory conditions, Treatment of acute respiratory failure.
At a glance
| Generic name | Oxis |
|---|---|
| Also known as | LABA |
| Sponsor | Fundacio Privada Mon Clinic Barcelona |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
It works by delivering a high concentration of oxygen to patients with respiratory conditions, such as chronic obstructive pulmonary disease (COPD) or pneumonia. This can help to improve oxygenation of the body's tissues and organs, reducing symptoms and improving quality of life.
Approved indications
- Treatment of hypoxemia in patients with chronic obstructive pulmonary disease (COPD) or other respiratory conditions
- Treatment of acute respiratory failure
Common side effects
- Oxygen toxicity
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (PHASE4)
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxis CI brief — competitive landscape report
- Oxis updates RSS · CI watch RSS
- Fundacio Privada Mon Clinic Barcelona portfolio CI